ID   A2780-NiraR
AC   CVCL_E5I4
DR   CCRID; 4201PAT-CCTCC02086
RX   Patent=US20240263142;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202299.
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI_176844; Niraparib.
CC   Sequence variation: Mutation; HGNC; HGNC:795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Glu365Lys (c.1093G>A); ClinVar=VCV000419222; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:17271; RRAS2; Simple; p.Gln72Leu (c.215A>T); ClinVar=VCV000009447; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   Patent=US20240263142;
RA   Lu W.-G., Lin H., Shen Y.-Q., Xu J.-F.;
RT   "Human ovarian cancer niraparib-resistant cell strain and use
RT   thereof.";
RL   Patent number US20240263142, 08-Aug-2024.
//